Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration

被引:5
|
作者
Liutkeviciene, Rasa [1 ,2 ]
Vilkeviciute, Alvita [2 ]
Slavinskaite, Aiste [3 ]
Petrauskaite, Aiste [3 ]
Tatarunas, Vacis [4 ]
Kriauciuniene, Loresa [1 ,2 ]
机构
[1] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania
[2] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania
[3] Lithuanian Univ Hlth Sci, Med Acad, LT-50009 Kaunas, Lithuania
[4] Lithuanian Univ Hlth Sci, Med Acad, Cardiol Inst, Eiveniu 2, LT-50161 Kaunas, Lithuania
关键词
Age-related macular degeneration; SLCO1B1; Gene polymorphisms; Serum SLCO1B1; CARDIOVASCULAR RISK-FACTORS; STATIN-INDUCED MYOPATHY; OATP-C; POLYMORPHISMS; DISEASE; ATORVASTATIN; EXPRESSION; ASSOCIATION; MACULOPATHY; TRANSPORTER;
D O I
10.1016/j.gene.2018.07.031
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To determine SLCOIBI rs4149056 and rs2306283 gene polymorphisms and SLCO1B1 serum levels in patients with early and exudative age-related macular degeneration. Materials and methods: The study enrolled 206 patients with exudative AMD, 253 patients with early AMD and 301 control subjects. DNA was extracted from peripheral venous blood leukocytes using commercial kits. Genotyping of SLCO1B1 rs4149056 and rs2306283 was carried out using a real-time polymerase chain reaction (RT-PCR) method. Serum SLCO1B1 levels were measured using SLCO1B1 ELISA kit. Results: We found statistically significant differences in genotype (T/T, T/C and C/C) distribution of SLCO1B1 rs4149056 variant between the patients with exudative AMD and control group (52.4%, 47.6% and 0% vs. 64.8%, 31.6% and 13.7%, respectively, p < 0.001). Univariate binary logistic regression analysis showed that age was a risk factor for exudative AMD development. Also, T/C variant was associated with 1.9-fold increased Odds ratio of exudative AMD development under a codominant model (OR = 1.863; 95% CI: 1.290;2.689; p < 0.001). The results remained of the same statistical significance after multivariate analysis. On the other hand, C allele was associated with 1.6-fold increased odds ratio of exudative AMD development (OR = 1.563; 95% CI: 1.035;2.359; p = 0.034) only after adjustment for age. No significant associations were found in analysis of genotypes and alleles at rs2306283. Serum SLCO1B1 concentration was significantly higher in early AMD patients than in healthy controls (median, IQR: 2.92 ng/ml, 5.01 ng/ml versus 1.26 ng/ml, 2.63 ng/ml, respectively, p = 0.025), as well as in exudative AMD patients than in controls (median, IQR: 2.72 ng/ml, 5.71 ng/ml versus 1.26 ng/ml, 2.63 ng/ml, respectively, p = 0.002). Furthermore, subjects with rs4149056 T/C genotype had higher SLCO1B1 serum levels than those with T/T genotype (median, IQR: 3.73 ng/ml, 3.14 ng/ml versus 1.23 ng/ml, 1.47 ng/ml, respectively, p = 0.037). Conclusion: Our study determined that SLCO1B1 (c.521 T > C) rs4149056 T/C genotype and C allele may be associated with exudative age-related macular degeneration, as well as with elevated serum SLCO1B1 levels. Also, higher serum SLCO1B1 levels were found to be associated with early and exudative age-related macular degeneration.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 50 条
  • [31] Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
    Song, Gonjin
    Chung, Jee-Eun
    Yee, Jeong
    Lee, Kyung-Eun
    Park, Kyungsoo
    Gwak, Hye-Sun
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [32] EFFECTS OF SLCO1B1 GENETIC POLYMORPHISM ON THE PHARMACOKINETICS OF PITAVASTATIN IN KOREANS
    Choi, C., I
    Bae, J. W.
    Lee, H., I
    Kim, M. J.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 79 - 79
  • [33] SLCO1B1 genetic variation and hormone therapy in menopausal women
    Moyer, Ann M.
    de Andrade, Mariza
    Faubion, Stephanie S.
    Kapoor, Ekta
    Dudenkov, Tanda
    Weinshilboum, Richard M.
    Miller, Virginia M.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (08): : 877 - 882
  • [34] Rare SLCO1B1 variants found to significantly affect methotrexate disposition
    Miller, Sarah
    PHARMACOGENOMICS, 2012, 13 (03) : 255 - 256
  • [36] Association of SLCO1B1 genetic variants with neonatal hyperbilirubinemia: a consolidated analysis of 36 studies
    Hanieh Talebi
    Seyed Alireza Dastgheib
    Maryam Vafapour
    Reza Bahrami
    Amirhossein Shahbazi
    Seyedeh Elham Shams
    Mahsa Danaei
    Heewa Rashnavadi
    Maryam Yeganegi
    Melina Pourkazemi
    Amirmasoud Shiri
    Maryam Aghasipour
    Hossein Neamatzadeh
    BMC Pediatrics, 25 (1)
  • [37] SLCO1B1 variants and statin-induced myopathy -: A genomewide study
    Link, E.
    Parish, S.
    Armitage, J.
    Bowman, L.
    Heath, S.
    Matsuda, F.
    Gut, I.
    Lathrop, M.
    Collins, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (08): : 789 - 799
  • [38] Genetic variations and frequencies of major Haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than*15
    Kim, Su-Ryang
    Saito, Yoshiro
    Sai, Kimie
    Kurose, Kouichi
    Maekawa, Keiko
    Kaniwa, Nahoko
    Ozawa, Shogo
    Kamatani, Naoyuki
    Shirao, Kuniaki
    Yamamoto, Noboru
    Hamaguchi, Tetsuya
    Kunitoh, Hideo
    Ohe, Yuichiro
    Yamada, Yasuhide
    Tamura, Tomohide
    Yoshida, Teruhiko
    Minami, Hironobu
    Ohtsu, Atsushi
    Saijo, Nagahiro
    Sawada, Jun-ichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2007, 22 (06) : 456 - 461
  • [39] Effects of the SLCO1B1 *1 and SLCO1B1 *5 polymorphisms on IL-6 and IL-10 levels in patients under pravastatin treatment prior to inguinal hernia repair
    Irazema Cardenas-Rojas, Martha
    Delgado-Enciso, Ivan
    Margarita Baltazar-Rodriguez, Luz
    Guzman-Esquivel, Jose
    Ramirez-Flores, Mario
    INTERNATIONAL JOURNAL OF SURGERY, 2016, 27 : 105 - 109
  • [40] GENETIC POLYMORPHISMS IN SLCO1B1 ARE NOT ASSOCIATED WITH ALTERED VOXILAPREVIR EXPOSURE.
    Garrison, K.
    Song, Q.
    Stamm, L.
    Ling, J.
    Mathias, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S34 - S34